trial

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

NCTId NCT03397134
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 515 (actual)
Sponsored by Minerva Neurosciences
Primary completion 2020-05-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
515 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2017-12-15
Primary completion
2020-05-26
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Roluperidone

Sponsors

Minerva NeurosciencesLead Sponsor

Sites

39 total
Rogers, United StatesCulver City, United StatesGarden Grove, United StatesNational City, United StatesTorrance, United StatesNorth Miami, United StatesOakland Park, United StatesAtlanta, United StatesChicago, United StatesBerlin, United StatesOrangeburg, United StatesDeSoto, United States

Linked catalysts

1
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patient — primary completion2020-05-26

Facts & assertions

4 sourced
Enrollment
515
Phase
PHASE3
Primary Completion Date
2020-05-26
Status
COMPLETED
relationships
The graph out of here
drug
Roluperidone
drug
lead_sponsor
Minerva Neurosciences
company
indication
Negative Symptoms of Schizophrenia
indication